Loading
Neratinib, a tablet for HER2-positive breast cancer, causes diarrhoea in almost everyone. Prevent it in one of two ways agreed before you start: loperamide on a fixed schedule from the first tablet for eight weeks, or a lower starting dose built up over two weeks. Drink about two litres a day, and call your team at once if diarrhoea is severe or comes with weakness, dizziness or fever.
Without prophylaxis, diarrhoea occurred in 95 per cent of people in ExteNET, grade 3 in 40 per cent, with a median onset of grade 3 or worse at day 8. The US label now offers two strategies from the first dose. Either loperamide prophylaxis for the first 56 days (4 mg three times daily in weeks 1 and 2, 4 mg twice daily in weeks 3 to 8, then as needed up to 16 mg a day, titrated to one or two bowel movements a day), or a two-week neratinib dose escalation (120 mg a day in week 1, 160 mg in week 2, 240 mg from week 3) with loperamide as needed. In the open-label phase II CONTROL trial, six non-comparative cohorts of 563 people starting extended adjuvant neratinib all had less grade 3 diarrhoea than historical controls; it was lowest with the two-week escalation (13 per cent) and highest with colestipol plus loperamide as needed (33 per cent), and diarrhoea-related discontinuations were 3 per cent with the two-week escalation against 20 per cent with loperamide alone. The label's dose modification table sets when to adjust antidiarrhoeals, interrupt, reduce or stop.
Why: Diarrhoea usually starts in the first weeks; either strategy, started on day one, makes severe diarrhoea much less likely.
“Alternatively, a 2-week NERLYNX dose escalation approach prior to initiation of the recommended treatment regimen with NERLYNX can also be considered for diarrhea management”
Puma Biotechnology, via DailyMed, US National Library of Medicine 2026
Why: Taking loperamide on a schedule from the start keeps diarrhoea mild while the bowel adapts.
“Weeks 1–2 (days 1–14) 4 mg three times daily Weeks 3–8 (days 15–56) 4 mg twice daily Weeks 9–Discontinuation of NERLYNX 4 mg as needed, not to exceed 16 mg per day; titrate dosing to achieve 1–2 bowel movements per day”
Puma Biotechnology, via DailyMed, US National Library of Medicine 2026
Why: A lower dose at first lets the bowel adjust before the full dose; in the CONTROL trial it gave the least severe diarrhoea.
“Week 1 (days 1–7) 120 mg daily (three 40 mg tablets) Week 2 (days 8–14) 160 mg daily (four 40 mg tablets) Week 3 and onwards 240 mg daily (six 40 mg tablets, recommended dose)”
Puma Biotechnology, via DailyMed, US National Library of Medicine 2026
Why: One or two bowel movements a day shows the dose is right: fewer suggests too much loperamide, more that diarrhoea is building.
“Instruct patients to maintain 1–2 bowel movements per day and on how to use antidiarrheal treatment regimens.”
Puma Biotechnology, via DailyMed, US National Library of Medicine 2026
Why: Most diarrhoea on neratinib settles with more antidiarrhoeal medicine and fluids without stopping the drug.
“Adjust antidiarrheal treatment Diet modifications Fluid intake of ~2 L/day should be maintained to avoid dehydration”
Puma Biotechnology, via DailyMed, US National Library of Medicine 2026
Why: Stopping briefly lets the bowel recover; restarting at a lower dose after a slow recovery prevents a repeat.
“If diarrhea resolves to ≤Grade 1 in one week or less, then resume NERLYNX treatment at the same dose If diarrhea resolves to ≤Grade 1 in longer than one week, then resume NERLYNX treatment at reduced dose”
Puma Biotechnology, via DailyMed, US National Library of Medicine 2026
Why: Life-threatening diarrhoea, or diarrhoea that persists at the lowest dose, means the drug cannot be given safely.
“Permanently discontinue NERLYNX treatment Diarrhea recurs to Grade 2 or higher at 120 mg per day Permanently discontinue NERLYNX treatment”
Puma Biotechnology, via DailyMed, US National Library of Medicine 2026
Why: Severe diarrhoea on neratinib has led to dehydration, low blood pressure and kidney failure.
“Advise patients to inform their healthcare provider immediately if severe (≥Grade 3) diarrhea or diarrhea associated with weakness, dizziness, or fever occurs during treatment with NERLYNX”
Puma Biotechnology, via DailyMed, US National Library of Medicine 2026
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
The current US label (July 2026) makes both strategies standard from the first dose: scheduled loperamide for 56 days, or a two-week dose escalation with loperamide as needed. On the evidence read, the two-week escalation gave the lowest rates of grade 3 diarrhoea (13 per cent) and of diarrhoea-related discontinuation (3 per cent) in CONTROL, against 31 and 20 per cent with loperamide alone; but CONTROL's cohorts were not randomised against each other, so the comparison is indirect. No graded guideline on neratinib diarrhoea was found.
Puma Biotechnology, via DailyMed, US National Library of Medicine 2026 · The Breast 2023
Where it differs: Neratinib 160 mg a day on days 1 to 14 and 200 mg a day on days 15 to 28, then 240 mg, with loperamide as needed.
Evidence: Grade 3 diarrhoea 27 per cent and diarrhoea-related discontinuation 6 per cent, both higher than the two-week schedule; not in the label. Open-label, non-comparative cohort.
Where it differs: Adds budesonide 9 mg once daily on days 1 to 28 to scheduled loperamide.
Evidence: Grade 3 diarrhoea 28 per cent and diarrhoea-related discontinuation 11 per cent, against 31 and 20 per cent with loperamide alone. Open-label, non-comparative cohort.
Where it differs: Adds the bile acid binder colestipol 2 g twice daily on days 1 to 28, to scheduled loperamide (CL) or to loperamide as needed (CL-PRN).
Evidence: Grade 3 diarrhoea 21 per cent with scheduled loperamide and 33 per cent with loperamide as needed; discontinuations 4 and 8 per cent. Open-label, non-comparative cohorts. The label says other agents may be added to loperamide as clinically indicated.
The Breast 2023 · Puma Biotechnology, via DailyMed, US National Library of Medicine 2026
Neratinib, a tablet for HER2-positive breast cancer, gives almost everyone diarrhoea, and many stop it early because of that. Starting at half the dose and building up over two weeks gave the least severe diarrhoea of any strategy tested, and the US label now allows it. The evidence comes from cohorts that were not randomised against each other, so a direct comparison is still owed.
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Grade 3 diarrhoea and discontinuation by strategy in CONTROL “All strategies reduced grade ≥3 diarrhea with the lowest incidence in DE1 (DE1 13%; colestipol + loperamide [CL] 21%, DE2 27%; budesonide + loperamide [BL] 28%; loperamide [L] 31%; colestipol + loperamide as needed [CL-PRN] 33%).” | open-label phase II, six non-comparative cohorts (n = 563) | The Breast 2023 |
| Without required prophylaxis (ExteNET), grade 3 diarrhoea occurred in 40 per cent “In the NERLYNX arm, Grade 3 diarrhea occurred in 40% and Grade 4 diarrhea occurred in 0.1% of patients.” | Label incidence from the registration trial | Puma Biotechnology, via DailyMed, US National Library of Medicine 2026 |
Shares CTCAE toxicity grading (grade 3-4 adverse events) and the tags protocol, diarrhoea, supportive-care.
Shares the tags protocol, supportive-care.
Shares the tags protocol, supportive-care.
Shares the tags protocol, supportive-care.
Shares the tags protocol, supportive-care.
Shares the tags protocol, supportive-care.
Shares the tags protocol, supportive-care.
Shares the tags protocol, supportive-care.